Physician profile
Victor Chang
NPI 1558537191
$6,506.00
in general payments reported to CMS, 2019-2025
37 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $194 · 2021: $356 · 2022: $769 · 2023: $733 · 2024: $1,001 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,949 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,949.15 |
| Education | $125.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $755.06 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $571.45 | 2024-2025 | Tavneos, Krystexxa, Uplizna |
| Vifor Pharma, INC. | $568.22 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $526.57 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $482.47 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $366.47 | 2021-2025 | Filspari |
| Akebia Therapeutics INC | $364.98 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $236.99 | 2021-2025 | |
| Ardelyx, INC. | $232.73 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $232.43 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $220.94 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $202.11 | 2019-2024 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $143.01 | 2024-2025 | |
| Boston Scientific Corporation | $142.86 | 2022 | |
| Alexion Pharmaceuticals, INC. | $132.17 | 2024-2025 | Ultomiris |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.